• Progress in Medical Physics
• /
• v.31 no.4
• /
• pp.135-144
• /
• 2020

Purpose: Gafchromic films for proton dosimetry are dependent on linear energy transfers (LETs), resulting in dose underestimation for high LETs. Despite efforts to resolve this problem for single-energy beams, there remains a need to do so for multi-energy beams. Here, a bimolecular reaction model was applied to correct the under-response of spread-out Bragg peaks (SOBPs). Methods: For depth-dose measurements, a Gafchromic EBT3 film was positioned in water perpendicular to the ground. The gantry was rotated at 15° to avoid disturbances in the beam path. A set of films was exposed to a uniformly scanned 112-MeV pristine proton beam with six different dose intensities, ranging from 0.373 to 4.865 Gy, at a 2-cm depth. Another set of films was irradiated with SOBPs with maximum energies of 110, 150, and 190 MeV having modulation widths of 5.39, 4.27, and 5.34 cm, respectively. The correction function was obtained using 150.8-MeV SOBP data. The LET of the SOBP was then analytically calculated. Finally, the model was validated for a uniform cubic dose distribution and compared with multilayered ionization chamber data. Results: The dose error in the plateau region was within 4% when normalized with the maximum dose. The discrepancy of the range was <1 mm for all measured energies. The highest errors occurred at 70 MeV owing to the steep gradient with the narrowest Bragg peak. Conclusions: With bimolecular model-based correction, an EBT3 film can be used to accurately verify the depth dose of scanned proton beams and could potentially be used to evaluate the depth-dose distribution for patient plans.

• The Journal of Korean Society for Radiation Therapy
• /
• v.26 no.2
• /
• pp.183-189
• /
• 2014

Purpose : Intravenous contrast medium is a substance used to enhance the contrast of normal tissues or malignant tissues within the body. For this reason, intravenous contrast media have been extensively used form treatment-planning CT. However, when the patient is receiving proton therapy, there is no contrast medium in that moment. In this study, evaluate the influence of intravenous contrast medium on proton range and Spread-Out Bragg peak(SOBP) in Treatment Planning System(TPS). Materials and Methods : Hounsfield Unit(HU) value were measured by 20 liver cancer patients with phase change. and evaluate the proton range and SOBP on 5 liver proton treatment plan. By using the hand made water phantom measure the proton range and SOBP on proton treatment plan with changing HU and Depth. Results : Changing value(Pre contrast, Arterial phase, Portal phase) in liver cancer patient were ($58{\pm}5.7$, $75{\pm}9.5$, $117{\pm}14.6$ for liver tissue) and ($40{\pm}6.1$, $279{\pm}49.0$, $154{\pm}22.8$ for aorta), respectively. The mean difference of range was 2.5mm and SOBP was 1.4mm according to HU change. In phantom study, proton range was shorter and SOBP was narrowed with increasing HU. Conclusion : We verify that HU change lead to range and SOBP change in TPS. Additional study is required to verify that change of HU make range and SOBP be changed in actual substance.

• Journal of the Korean Society of Radiology
• /
• v.13 no.2
• /
• pp.253-260
• /
• 2019

Radiation dose enhancement is a method of increasing the cross section of interaction, thus increasing the deposited dose. This can contribute to linear energy transfer, LET and relative biological effectiveness, RBE. Previous studies on dose enhancement have been mainly focused on X, ${\gamma}-rays$, but in this study, the dose enhancement was analyzed for proton using Monte Carlo simulation using MCNP6. Based on the mathematical modeling method, energy spectrum and relative intensity of spread out Bragg-peak were calculated, and evaluated dose enhancement factor and dose distribution of dose enhancement material, such as aurum and gadolinium. Dose enhancement factor of 1.085-1.120 folds in aurum, 1.047-1.091 folds in gadolinium was shown. In addition, it showed a decrease of 95% modulation range and practical range. This may lead to an uncertain dose in the tumor tissue as well as dose enhancement. Therefore, it is necessary to make appropriate corrections for spread out Bragg-peak and practical range from mass stopping power. It is expected that Monte Carlo simulation for dose enhancement will be used as basic data for in-vivo and in-vitro experiments.

• Journal of the Korean Society of Radiology
• /
• v.13 no.7
• /
• pp.917-924
• /
• 2019

The passive scattering system nozzle of the proton therapy accelerator was simulated to evaluate the neutrons generated by each component in each nozzle by energy. The Monte Carlo N-Particle code was used to implement spread out Bragg peak with proton energy 220 MeV, reach 20 cm, and 6 cm length used in the treatment environment. Among the proton accelerator components, neutrons were the highest in scatterers, and the neutron flux decreased as it moved away from the central flux of the proton. This study can be used as a basic data for the evaluation of the radiation necessary for the maintenance and dismantling of proton accelerators.

• Journal of the Korean Society of Radiology
• /
• v.15 no.6
• /
• pp.771-779
• /
• 2021

It is necessary to overlap several peaks to form spread out Bragg peak (SOBP) in order to cover the tumor volume because a mono-energetic proton beam forms a narrow Bragg peak. The tumor density has been considered as a brain tissue and then the absorbed dose of the tumor is calculated using Monte Carlo simulations. However, densities of tumors were not a constant. In this study, the SOBP of proton beams was calculated according to changing density of tumors by using Geant4. Tumors were selected as 10 mm and 20 mm width which were the treatment range in the brain phantom. The energies and relative weights of the proton beams were calculated using mathematical formula to form the SOBP suitable for the location and size of the tumor. As the density of the tumor was increased, the 95% modulation range and the practical range were decreased, and average absorbed dose in the 95% modulation range was increased. The change of the tumor density affects the dose distribution of the proton beams, which results in short SOBP within the tumor volume. The consideration of the tumor density affects the determination of the range, so that the margin of the treatment volume can be minimized, and the advantages of proton therapy can be maximized.

• Proceedings of the Korean Society of Medical Physics Conference
• /
• 2002.09a
• /
• pp.252-254
• /
• 2002

A new protocol for dosimetry in external beam radiotherapy is published by the Japan Society of Medical Physics (JSMP) in 2002. The protocol deals with proton and heavy ion beams as well as photon and electron beams, in accordance with IAEA Technical Report Series No. 398. To establish inter-institutional uniformity in proton beam dosimetry, an intercomparison program was carried out with the new protocol. The absorbed doses are measured with different cylindrical ionization chambers in a water phantom at a position of 30-mm residual range for a proton beam, that had range of 155 mm and a spread out Bragg peak (SOBP) of 60-mm width. As a result, the intercomparison showed that the use of the new protocol would improve the +/- 1.0 % (one standard deviation) and 2.7 % (maximum discrepancy) differences in absorbed doses stated by the participating institutions to +/- 0.3% and 0.9 %, respectively. The new protocol will be adopted by all of the participants.

• Progress in Medical Physics
• /
• v.30 no.4
• /
• pp.112-119
• /
• 2019

Purpose: The advantages of ocular proton therapy are that it spares the optic nerve and delivers the minimal dose to normal surrounding tissues. In this study, it developed a solid eye phantom that enabled us to perform quality assurance (QA) to verify the dose and beam range for passive single scattering proton therapy using a single phantom. For this purpose, a new solid eye phantom with a polymethyl-methacrylate (PMMA) wedge was developed using film dosimetry and an ionization chamber. Methods: The typical beam shape used for eye treatment is approximately 3 cm in diameter and the beam range is below 5 cm. Since proton therapy has a problem with beam range uncertainty due to differences in the stopping power of normal tissue, bone, air, etc, the beam range should be confirmed before treatment. A film can be placed on the slope of the phantom to evaluate the Spread-out Bragg Peak based on the water equivalent thickness value of PMMA on the film. In addition, an ionization chamber (Pin-point, PTW 31014) can be inserted into a hole in the phantom to measure the absolute dose. Results: The eye phantom was used for independent patient-specific QA. The differences in the output and beam range between the measurement and the planned treatment were less than 1.5% and 0.1 cm, respectively. Conclusions: An eye phantom was developed and the performance was successfully validated. The phantom can be employed to verify the output and beam range for ocular proton therapy.

• Journal of Life Science
• /
• v.17 no.8 s.88
• /
• pp.1100-1103
• /
• 2007

In proton therapy, the Bragg peak is spread out by modulating or degrading the energy of the particles to cover a well-defined target volume at a given depth. Proton transfer plays a key role in a variety of biological, the origin of the elements, tests of the standard model along with applications in medicine, industry and chemical phenomena such as water autoionization, fast proton diffusion, acid-base neutralization. We have studied the radiolysis of various natural resources and have evaluated the antioxidant activity of radiolysis products by proton beam. The most of antioxidant activities of natural resources were decreased with increasing proton fluence. Proton beam induced antioxidant activities both in 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) assay and 2,2'-azinobis(3-ethylbenzot hialozinesulfonic acid) cation radical $(ABTS^{.+})$ assay by a dose dependent fashion.

• The Journal of Korean Society for Radiation Therapy
• /
• v.25 no.2
• /
• pp.107-113
• /
• 2013

Purpose: To verify accuracy of respiratory gated proton therapy by measuring and analyzing proton beam delivered when respiratory gated proton therapy is being performed in our institute. Materials and Methods: The plan data of 3 patients who took respiratory gated proton therapy were used to deliver proton beam from proton therapy system. The manufactured moving phantom was used to apply respiratory gating system to reproduce proton beam which was partially irradiated. The key characteristics of proton beam, range, spreat-out Bragg peak (SOBP) and output factor were measured 5 times and the same categories were measured in the continuous proton beam which was not performed with respiratory gating system. Multi-layer ionization chamber was used to measure range and SOBP, and Scanditronix Wellhofer and farmer chamber was used to measure output factor. Results: The average ranges of 3 patients (A, B, C), who had taken respiratory gated proton therapy or not, were (A) 7.226, 7.230, (B) 12.216, 12.220 and (C) 19.918, 19.920 $g/cm^2$ and average SOBP were (A) 4.950, 4.940, (B) 6.496, 6.512 and (C) 8.486, 8.490 $g/cm^2$. And average output factor were (A) 0.985, 0.984 (B) 1.026, 1.027 and (C) 1.138, 1.136 cGy/MU. The differences of average range were -0.004, -0.004, -0.002 $g/cm^2$, that of SOBP were 0.010, -0.016, -0.004 $g/cm^2$ and that of output factor were 0.001, -0.001, 0.002 cGy/MU. Conclusion: It is observed that the range, SOBP and output factor of proton beam delivered when respiratory gated proton therapy is being performed have the same beam quality with no significant difference compared to the proton beam which was continuously irradiated. Therefore, this study verified the quality of proton beam delivered when respiratory gated proton therapy and confirmed the accuracy of proton therapy using this.

• Progress in Medical Physics
• /
• v.30 no.1
• /
• pp.14-21
• /
• 2019

Purpose: To report the initial experience of patient-specific quality assurance (pQA) for the wobbling and line-scanning proton therapy at Samsung Medical Center. Materials and Methods: The pQA results of 89 wobbling treatments with 227 fields and 44 line-scanning treatments with 118 fields were analyzed from December 2015 to June 2016. For the wobbling method, proton range and spread-out Bragg peak (SOBP) width were verified. For the line-scanning method, output and two-dimensional dose distribution at multiple depths were verified by gamma analysis with 3%/3 mm criterion. Results: The average range difference was -0.44 mm with a standard deviation (SD) of 1.64 mm and 0.1 mm with an SD of 0.53 mm for the small and middle wobbling radii, respectively. For the line-scanning method, the output difference was within ${\pm}3%$. The gamma passing rates were over 95% with 3%/3 mm criterion for all depths. Conclusions: For the wobbling method, proton range and SOBP width were within the tolerance levels. For the line-scanning method, the output and two-dimensional dose distribution showed excellent agreement with the treatment plans.